Specialst Programme : Aldo-keto reductases (AKRs), BaP Therapgy and drug redeployment strategies for accelerating thraphy development for haematological cancers

Medicine & Life Sciences

1. Valproic Acid 100%
2. Myeloid Cells 93%
3. Acute Myeloid Leukemia 87%
4. Reactive Oxygen Species 73%
5. Bezafibrate 68%
6. Antioxidants 67%
7. Medroxyprogesterone Acetate 58%
8. Drug Repositioning 31%
9. Elderly 30%
10. Safety 26%
11. Myelodysplastic Syndromes 25%
12. Contraceptive Agents 24%
13. Lipid Peroxidation 21%
14. Fatty Acids 19%
15. Hormones 16%
16. Lipids 14%
17. Cell Line 13%
18. In Vitro Techniques 9%